Table 2.

Significant fold differences (P < 0·05) in gene expression between peripheral blood mononuclear cells (PBMC) from patients with early diffuse cutaneous systemic sclerosis (dcSSc) (E) or late dcSSc (L) and controls (C) after culture in control medium (M) or medium with added type I collagen (CI). Positive values indicate fold higher and negative indicate fold lower levels of gene expression in indicated dcSS samples compared to samples from controls.

Gene	UniGene	OMIM	Full gene name	E versus C in M	L versus C in M	E versus C in CI	L versus C in CI
A20	Hs.211600	191163	Tumour necrosis factor, alpha-induced protein 3	–2·8		–2·0
ACVR2	Hs.470174	102581	Activin A receptor, type II	+4·1	+4·6	+5·3	+6·1
ALK3	Hs.524477	601299	Bone morphogenetic protein receptor, type IA	+2·9	+3·8	+3·4	+4·0
ALK5	Hs.494622	190181	Transforming growth factor, beta receptor I			–3·1
AMH	Hs.112432	600957	Anti-Mullerian hormone		+2·2	+2·5	+3·2
AMHR2	Hs.659889	600956	Anti-Mullerian hormone receptor, type II	+2·2	+2·4	+1·8	+1·8
BAD	Hs.370254	603167	BCL2-antagonist of cell death	+2·8		+2·5
CALM2	Hs.643483	114182	Calmodulin 2 (phosphorylase kinase, delta)		+2·6		+2·5
CBP	Hs.459759	600140	CREB binding protein	+2·7	+3·3	+2·2	+2·5
CCL2	Hs.303649	158105	Chemokine (C-C motif) ligand 2	+3·7	+3·3	+2·7	+3·1
CCL5	Hs.514821	187011	Chemokine (C-C motif) ligand 5	+2·5	+2·4	+2·1	+1·9
CCR10	Hs.278446	600240	G protein-coupled receptor 2	–2·0
CCR5	Hs.450802	601373	Chemokine (C-C motif) receptor 5	+2·4	+3·0	+3·6	+2·7
CDKN1A	Hs.370771	116899	Cyclin-dependent kinase inhibitor 1A (p21, Cip1)	–3·1	–1·8	–3·0	–2·3
CDKN2B	Hs.72901	600431	Cyclin-dependent kinase inhibitor 2B	+3·9	+5·1	+3·5	+3·9
CREB	Hs.584750	123810	CAMP responsive element binding protein 1	+2·8	+2·5	+2·3	+2·0
CTLA4	Hs.247824	123890	Cytotoxic T-lymphocyte-associated protein 4	+3·1	+3·5	+3·1	+2·8
CX3CL1	Hs.531668	601880	Chemokine (C-X3-C motif) ligand 1	–1·8		–2·1	–1·9
CXCL2	Hs.590921	139110	Chemokine (C-X-C motif) ligand 2	+2·1	+2·3	+3·0	+2·5
CXCL3	Hs.89690	139111	Chemokine (C-X-C motif) ligand 3			+1·8
EGR1	Hs.326035	128990	Early growth response 1			+4·5	+4·8
EGR2	Hs.1395	129010	Early growth response 2	+6·2		+8·2
FasL	Hs.2007	134638	Tumour necrosis factor (ligand) superfamily, member 6	+2·7	+2·2
FCER1A	Hs.897	147140	Fc fragment of IgE, high affinity I, receptor for; alpha polypeptide				+4·0
FOSL1	Hs.283565	136515	FOS-like antigen 1		+2·4	+2·3	+2·1
GATA4	Hs.431009	603693	Zinc finger protein, multitype 2	–1·7		–2·0
GM-CSF	Hs.1349	138960	Colony stimulating factor 2 (granulocyte–macrophage)			–3·0	–2·7
GSK3A	Hs.466828	606786	Glycogen synthase kinase 3 alpha	–1·9	–1·6	–1·6
IGF1	Hs.160562	147440	Insulin-like growth factor 1 (somatomedin C)				+1·8
IL11	Hs.467304	147681	Interleukin 11				+2·1
IL12Rβ2	Hs.567294	601642	Interleukin 12 receptor, beta 2			–2·8
NCK2	Hs.529244	604930	NCK adaptor protein 2	+2·1	+2·8	+2·0	+2·8
NFKB2	Hs.73090	164012	Nuclear factor of kappa light polypeptide gene enhancer in B cells 2	+1·7	+1·6	+1·9
NFRKB	Hs.530539	164013	Nuclear factor related to kappa B binding protein		+2·8	+2·6	+3·1
SELE	Hs.89546	131210	Selectin E	–1·9	–2·1	–2·1	–2·2
SELL	Hs.719894	153240	Selectin L	–4·8	–4·7
STAT1	Hs.699271	600555	Signal transducer and activator of transcription 1	+2·4	+2·0	+2·4	+2·8
TLR4	Hs.174312	603030	Toll-like receptor 4			–2·8
TLR7	Hs.659215	300365	Toll-like receptor 7			–2·0	–1·6
TLR8	Hs.660543	300366	Toll-like receptor 8	+2·2	+3·2		+2·0
TRAF1	Hs.531251	601711	TNF receptor-associated factor 1	+3·1	+3·9	+2·0	+2·2
TRAF5	Hs.523930	602356	TNF receptor-associated factor 5		+4·3		+4·2